Fischbach R
Br J Clin Pharmacol. 1983;16 Suppl 1(Suppl 1):157S-160S. doi: 10.1111/j.1365-2125.1983.tb02288.x.
This double-blind study in 60 hospitalized female patients comparing midazolam 15 mg, oxazepam 15 mg and placebo, demonstrated an inter-group difference in favour of midazolam with regard to efficacy. The sleep parameters of onset latency and duration were improved by midazolam. All three compounds were very well tolerated and no withdrawal symptoms were observed. Midazolam, in an oral dose of 15 mg, can thus be regarded as an effective, well-tolerated agent for the treatment of sleep disorders.
这项针对60名住院女性患者的双盲研究，比较了15毫克咪达唑仑、15毫克奥沙西泮和安慰剂，结果表明在疗效方面，组间差异有利于咪达唑仑。咪达唑仑改善了入睡潜伏期和睡眠时间的睡眠参数。所有三种化合物的耐受性都非常好，未观察到戒断症状。因此，口服剂量为15毫克的咪达唑仑可被视为治疗睡眠障碍的一种有效且耐受性良好的药物。
